Biology Reference
In-Depth Information
67. Burton EA, Glorioso JC (2001) Multi-modal
combination gene therapy for malignant gli-
oma using replication-defective HSV vectors.
Drug Discov Today 6:347-356
68. Mizuno H, Yanoma S, Nishimura G, Hattori
S, Ito T, Okudera K, Tsukuda M (2000)
Therapeutic effi ciency of IL-2 gene trans-
duced tumor vaccine for head and neck carci-
noma. Cancer Lett 152:175-185
69. Toda M, Martuza RL, Rabkin SD (2000)
Tumor growth inhibition by intratumoral inoc-
ulation of defective herpes simplex virus vectors
expressing granulocyte-macrophage colony-
stimulating factor. Mol Ther 2:324-329
70. Krisky DM, Marconi PC, Oligino TJ, Rouse
RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso
JC (1998) Development of herpes simplex
virus replication-defective multigene vectors
for combination gene therapy applications.
Gene Ther 5:1517-1530
71. Marconi P, Tamura M, Moriuchi S, Krisky
DM, Niranjan A, Goins WF, Cohen JB,
Glorioso JC (2000) Connexin 43-enhanced
suicide gene therapy using herpesviral vectors.
Mol Ther 1:71-81
72. Wolfe D, Niranjan A, Trichel A, Wiley C,
Ozuer A, Kanal E, Kondziolka D, Krisky D,
Goss J, Deluca N et al (2004) Safety and biodis-
tribution studies of an HSV multigene vector
following intracranial delivery to non-human
primates. Gene Ther 11:1675-1684
73. Poliani PL, Brok H, Furlan R, Ruffi ni F,
Bergami A, Desina G, Marconi PC, Rovaris
M, Uccelli A, Glorioso JC et al (2001)
Delivery to the central nervous system of a
nonreplicative herpes simplex type 1 vector
engineered with the interleukin 4 gene pro-
tects rhesus monkeys from hyperacute auto-
immune encephalomyelitis. Hum Gene Ther
12:905-920
74. Puskovic V, Wolfe D, Goss J, Huang S, Mata
M, Glorioso JC, Fink DJ (2004) Prolonged
biologically active transgene expression driven
by HSV LAP2 in brain in vivo. Mol Ther
10:67-75
75. Rasmussen M, Kong L, Zhang GR, Liu M,
Wang X, Szabo G, Curthoys NP, Geller AI
(2007) Glutamatergic or GABAergic neuron-
specifi c, long-term expression in neocortical
neurons from helper virus-free HSV-1 vectors
containing the phosphate-activated glutamin-
ase, vesicular glutamate transporter-1, or glu-
tamic acid decarboxylase promoter. Brain Res
1144:19-32
76. Glorioso JC, Mata M, Fink DJ (2003)
Exploiting the neurotherapeutic potential of
peptides: targeted delivery using HSV vec-
tors. Expert Opin Biol Ther 3:1233-1239
77. Martins I, Pinto M, Wilson SP, Lima D,
Tavares I (2008) Dynamic of migration of
HSV-1 from a medullary pronociceptive cen-
tre: antinociception by overexpression of the
preproenkephalin transgene. Eur J Neurosci
28:2075-2083
78. Jeyaretna DS, Rabkin SD, Martuza RL
(2007) Oncolytic herpes simplex virus ther-
apy for peripheral nerve tumors. Neurosurg
Focus 22:E4
79. Haseley A, Alvarez-Breckenridge C,
Chaudhury AR, Kaur B (2009) Advances in
oncolytic virus therapy for glioma. Recent Pat
CNS Drug Discov 4:1-13
80. Todo T, Rabkin SD, Martuza RL (2000)
Evaluation of ganciclovir-mediated enhance-
ment of the antitumoral effect in oncolytic,
multimutated herpes simplex virus type 1
(G207) therapy of brain tumors. Cancer Gene
Ther 7:939-946
81. Miyatake S, Martuza RL, Rabkin SD (1997)
Defective herpes simplex virus vectors express-
ing thymidine kinase for the treatment of
malignant glioma. Cancer Gene Ther 4:
222-228
82. Kanai R, Tomita H, Hirose Y, Ohba S,
Goldman S, Okano H, Kawase T, Yazaki T
(2007) Augmented therapeutic effi cacy of an
oncolytic herpes simplex virus type 1 mutant
expressing ICP34.5 under the transcriptional
control of musashi1 promoter in the treat-
ment of malignant glioma. Hum Gene Ther
18:63-73
83. Kramm CM, Chase M, Herrlinger U, Jacobs
A, Pechan PA, Rainov NG, Sena-Esteves M,
Aghi M, Barnett FH, Chiocca EA et al (1997)
Therapeutic effi ciency and safety of a second-
generation replication-conditional HSV1 vec-
tor for brain tumor gene therapy. Hum Gene
Ther 8:2057-2068
84. Bannazadeh Baghi H, Bamdad T, Soleimanjahi
H (2009) The effect of herpes simplex virus
virion host shutoff gene- a new suicide gene-
on tumor cells. Iran Biomed J 13:185-189
85. Jones FE, Smibert CA, Smiley JR (1995)
Mutational analysis of the herpes simplex
virus virion host shutoff protein: evidence
that vhs functions in the absence of other viral
proteins. J Virol 69:4863-4871
86. Dambach MJ, Trecki J, Martin N, Markovitz
NS (2006) Oncolytic viruses derived from the
gamma34.5-deleted herpes simplex virus
recombinant R3616 encode a truncated UL3
protein. Mol Ther 13:891-898
87. Ward SL, Scheuner D, Poppers J, Kaufman
RJ, Mohr I, Leib DA (2003) In vivo replica-
tion of an ICP34.5 second-site suppressor
mutant following corneal infection correlates
Search WWH ::
Custom Search